8-K filed March 26, 2026, 7:59 PM ET ticker MGTX CIK 0001735438

earnings confidence high sentiment positive materiality 0.85

MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV

MeiraGTx Holdings plc

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.
Strategic JV with Hologen: $200M upfront, $230M additional funding for AAV-GAD, MeiraGTx holds 30% ownership.
Collaboration with Lilly: $75M upfront, >$400M milestones for AAV-AIPL1 and other ocular assets.
FY2025 net loss $114.2M ($1.42/share) vs $147.8M ($2.12/share) in FY2024; cash $68.2M.
Debt amendment: maturity extended to May 2027, $25M redemption by June 30, 2026, warrant price reduced to $8.00.

item 1.01 item 2.02 item 2.03 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-034904
form_type: 8-K
ticker: MGTX
cik: 0001735438
company_name: MeiraGTx Holdings plc
filed_at: 2026-03-26T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.031560+00:00
generated_at: 2026-05-15T08:51:46.672599+00:00
sec_items: ["1.01", "2.02", "2.03", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-034904
json_url: https://secwatch.observer/filing/0001104659-26-034904.json
markdown_url: https://secwatch.observer/filing/0001104659-26-034904.md
text_url: https://secwatch.observer/filing/0001104659-26-034904.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/mgtx-20260325x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

6c5c72a88e4014c280d6dbcd2871611891c89d3d

MeiraGTx Holdings plc amended senior notes with Perceptive Credit Holdings III, LP maturing May 2, 2027.

Under the Amendments, the Maturity Date (as defined under the Notes Purchase Agreement) has been extended from August 2, 2026 to May 2, 2027 and the Company has agreed to redeem a portion of the outstanding principal amount of the Notes (as defined under the Notes Purchase Agreement) equal to $25,000,000 on or before June 30, 2026.

SEC 8-K Item 2.03/2.04 confidence 0.9 SEC evidence

4c18a95bbce82a76d6e5530e11417ccf55976b26

MeiraGTx Holdings plc reported financial results for the year ended December 31, 2025.

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

bd0f4b66505151b0e8f3bc94b616e80b26662f3c

MeiraGTx Holdings plc amended Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates with Perceptive Credit Holdings III, LP valued at Extended Maturity Date from August 2, 2026 to May 2, 2027; agreed to redeem $25,000,000 principal on (effective 2026-03-25).

Item 1.01. Entry Into a Material Definitive Agreement. On March 25, 2026, MeiraGTx Holdings plc (the “Company”), as issuer, and its wholly-owned subsidiaries MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), and MeiraGTx Ireland DAC, a designated activity company limited by shares incorporated in Ireland (“MeiraGTx Ireland,” and together with MeiraGTx UK II, the “Subsidiary Guarantors”), the noteholders and other parties from time to time party to the Notes Purchase Agreement (as defined below), and Perceptive Credit Holdings III, LP, as administrative agent and noteholder under the Notes Purchase Agreement (“Perceptive”), entered into Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates (the “Amendments”). The Amendments amend (A) the Amended and Restated Notes Purchase Agreement and Guaranty, dated December 19, 2022, between the Company, the Subsidiary Guarantors, the noteholders and oth

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

Comparable filings

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release, material_agreement same SEC item: 1.01, 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

FSK

FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback

FS KKR Capital Corp May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 7.01, 9.01

same fact type: earnings_release, material_agreement same SEC item: 1.01, 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025

Filing page SEC filing

CRON

Cronos Q1 net revenue up 40% to $45.2M; authorizes $50M share buyback; CanAdelaar close extended to Sep 9

Cronos Group Inc. May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 1.01, 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

reference in such a filing or document. --- EX-99.1 (EX-99.1) --- Cronos Group Reports 2026 First Quarter Results Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net revenue in Israel, where PEACE

Filing page SEC filing

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

URG

Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced

UR-ENERGY INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

Commission this morning. Details on First Quarter 2026 Results First Quarter Results (1) ($ in millions, except per share data) 1Q26 1Q25 Net Revenue $ 627.8 $ 673.9 Loss from continuing operations, net of tax, GAAP $ (6.5) $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP $ (3.1) $ 23.2

Filing page SEC filing

LQDA

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

Comparable filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-26-034904

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.